The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?
Open Access
- 1 January 2008
- journal article
- review article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 10 (3) , 208
Abstract
Rheumatoid arthritis is a heterogeneous disease with respect to clinical manifestations, serologic abnormalities, joint damage and functional impairment. Predicting outcome in a reliable way to allow for strategic therapeutic decision-making as well as for prediction of the response to the various therapeutic modalities available today, especially biological agents, would provide means for optimization of care. In the present article, the current information on biological and clinical markers related to disease activity and joint damage as well as for predictive purposes is reviewed. It will be shown that the relationship of many biomarkers with disease characteristics is confounded by factors unrelated to the disease, and that only few biomarkers exist with some predictive value. Moreover, clinical markers appear of equal value as biomarkers for this purpose, although they likewise have limited capacity in these regards. The analysis suggests the search for better markers to predict outcomes and therapeutic responsiveness in rheumatoid arthritis needs to be intensified.Keywords
This publication has 92 references indexed in Scilit:
- Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker resultsAnnals of the Rheumatic Diseases, 2008
- Real-time quantitative PCR to detect changes in synovial gene expression in rheumatoid arthritis after corticosteroid treatmentAnnals of the Rheumatic Diseases, 2007
- Diurnal variation in serum levels of cartilage oligomeric matrix protein in patients with knee osteoarthritis or rheumatoid arthritisAnnals of the Rheumatic Diseases, 2006
- The heritable determinants of cartilage oligomeric matrix proteinArthritis & Rheumatism, 2006
- Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2005
- Compromised Function of Regulatory T Cells in Rheumatoid Arthritis and Reversal by Anti-TNFα TherapyJournal of Experimental Medicine, 2004
- Markers for type II collagen breakdown predict the effect of disease‐modifying treatment on long‐term radiographic progression in patients with rheumatoid arthritisArthritis & Rheumatism, 2004
- The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2002
- Long term anti-tumour necrosis factor α monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activationAnnals of the Rheumatic Diseases, 2002
- Biannual Radiographic Assessments of Hands and Feet in a Three‐Year Prospective Followup of Patients with Early Rheumatoid ArthritisArthritis & Rheumatism, 1992